Please Wait

Applying Filters...

Technical details about Sorafenib, learn more about the structure, uses, toxicity, action, side effects and more

Sorafenib

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

57 Suppliers, 19 USDMF, 2 CEP/COS, 1 JDMF, 11 EU WC, 8 KDMF, 8 NDC API, 41 Listed Suppliers

DEVELOPMENTS

7 Drug(s) in Development

7 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

INTERMEDIATES

17 Suppliers

17 Suppliers

DOSSIERs // Finished Dosage Forms

27 Dossiers, 6 FDA Orange Book, 6 Europe, 1 Canada, 3 Australia, 1 South Africa, 10 Listed Dossiers

RELATED EXCIPIENT COMPANIES

Suppliers, 15 Kerry, 13 BASF, 10 Corel Pharma Chem, 10 Roquette, 9 Sigachi Industries, 8 Microlex e.U, 6 Lonza Capsugel, 6 Gangwal Healthcare, 6 Seppic, 5 Ideal Cures Pvt Ltd, 5 Gangwal Chemicals, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 DFE Pharma, 3 Kima Chemical, 3 Vasa Pharmachem, 3 Prachin Chemical, 3 Actylis, 2 Seqens, 2 Nomisma Healthcare, 2 The Dow Chemical Company, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Pharmatrans-Sanaq, 1 Finar, 1 Jai Radhe Sales, 1 Ingredion Pharma Solutions, 1 ACG Worldwide, 1 Qualicaps, 1 SPI Pharma

EXCIPIENTS BY APPLICATIONS

43 Coating Systems & Additives, 25 Controlled & Modified Release, 24 Fillers, Diluents & Binders, 16 Disintegrants & Superdisintegrants, 14 Thickeners and Stabilizers, 13 Direct Compression, 12 Granulation, 11 Lubricants & Glidants, 8 Topical, 7 Film Formers & Plasticizers, 6 Co-Processed Excipients, 6 Taste Masking, 5 Empty Capsules, 5 Solubilizers, 4 Vegetarian Capsules, 3 Rheology Modifiers, 3 Chewable & Orodispersible Aids, 3 API Stability Enhancers, 2 Parenteral, 2 Coloring Agents, 2 Emulsifying Agents

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions, 4 Finished Drug Prices

MARKET PLACE

8 APIs, 11 DOSSIERS // FDF

PATENTS

4 US Patents, 9 Health Canada Patents

ANALYTICAL SOLUTION(s)

13 Other Ref. Standards

13 Other Ref. Standards

DIGITAL CONTENT

2 Data Compilation & Company Tracker #PharmaFlow, 102 News

Also known as: 475207-59-1, Nexavar, Sorafenib tosylate [usan], Sorafenib (tosylate), Sorafenib tosilate, Bay 54-9085

Molecular Formula

C₂₈H₂₄ClF₃N₄O₆S

Molecular Weight

637.0 g/mol

InChI Key

IVDHYUQIDRJSTI-UHFFFAOYSA-N

FDA UNII

5T62Q3B36J

A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy.

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide;4-methylbenzenesulfonic acid

2.1.2 InChI

InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)

2.1.3 InChI Key

IVDHYUQIDRJSTI-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

2.2 Other Identifiers

2.2.1 UNII

5T62Q3B36J

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic Acid Methyamide-4-methylbenzenesulfonate

2. Bay 43 9006

3. Bay 43-9006

4. Bay 439006

5. Bay 545 9085

6. Bay 545-9085

7. Bay 5459085

8. Bay 673472

9. Bay-545-9085

10. Bay-673472

11. Bay5459085

12. Nexavar

13. Sorafenib

14. Sorafenib N Oxide

15. Sorafenib N-oxide

2.3.2 Depositor-Supplied Synonyms

1. 475207-59-1

2. Nexavar

3. Sorafenib Tosylate [usan]

4. Sorafenib (tosylate)

5. Sorafenib Tosilate

6. Bay 54-9085

7. 475207-59-1 (tosylate)

8. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide 4-methylbenzenesulfonate

9. Chebi:50928

10. 5t62q3b36j

11. Mfcd08235032

12. Bay-54-9085

13. Sorafenib Tosilate (jan)

14. Sorafenib (nexavar)

15. Sorafenib Tosylate (usan)

16. Nexavar(r)

17. Dsstox_cid_27817

18. Dsstox_rid_82581

19. Dsstox_gsid_47839

20. 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-((2-(methylcarbamoyl)pyridin-4-yl)oxy)phenyl)urea Mono(4-methylbenzenesulfonate)

21. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n2-methylpyridine-2-carboxamide Mono (4-methylbenzenesulfonate)

22. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide;4-methylbenzenesulfonic Acid

23. Sorafenib Tosilate [jan]

24. Bay 43-9006 Tosylate

25. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide 4-methylbenzenesulfonate.

26. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-n-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic Acid

27. Cas-475207-59-1

28. Nsc-724772

29. Ncgc00167488-01

30. Unii-5t62q3b36j

31. Sr-00000000529

32. Orafenib Tosylate

33. Bay43-9006 Mono-p-tosylate

34. Bay 43-9006 Mono-p-tosylate

35. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-n-methylpyridine-2-carboxamide 4-methylbenzenesulfonate

36. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-n-methylpyridine-2-carboxamide 4-methylbenzenesulfonate

37. Nexavar (tn)

38. Nsc724772

39. Sorafenib - Nexavar

40. Sorafenib Tsoh Salt

41. Mls002415564

42. Sorafenib Tosylate [mi]

43. Chembl1200485

44. Dtxsid9047839

45. Sorafenib (bay-43-9006)

46. Hms2219e08

47. Hms3654i09

48. Sorafenib, P-toluenesulfonate Salt

49. Sorafenib Tosilate [mart.]

50. Sorafenib Tosilate [who-dd]

51. Sorafenib Tosylate [usp-rs]

52. Tox21_112489

53. Hy-10201a

54. S1040

55. Akos015924650

56. Akos027469919

57. Tox21_112489_1

58. Ac-6799

59. Ccg-208000

60. Cs-0164

61. Nd-0228

62. Sorafenib Tosylate [orange Book]

63. Ncgc00167488-08

64. Sorafenib Tosilate [ep Monograph]

65. 2-pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-n-methyl-, Mono(4-methylbenzenesulfonate)

66. Bs164414

67. Smr001339079

68. Sorafenib Tosylate [usp Monograph]

69. Sy012324

70. Bcp0726000112

71. Am20090612

72. Ft-0650737

73. Ft-0698449

74. Sw202562-3

75. Ec-000.2356

76. A25518

77. D06272

78. S-8502

79. 207s591

80. Q-201729

81. Sr-00000000529-5

82. 2,5-dioxo-1,4-cyclohexanedicarboxylicaciddimethylester

83. Q27122250

84. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide Tosylate

85. 2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-n-methyl-, 4-methylbenzenesulfonate (1:1)

86. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-n-methylpyridine-2-carboxamide 4-methylbenzenesulphonate

87. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-n-methylpicolinamide4-methylbenzenesulfonate

88. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-2-pyridinecarboxamide Tosylate

89. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide;hydron;4-methylbenzenesulfonate

90. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-n-methylpyridine-2-carboxamide Tosylate

91. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n -methylpyridine-2-carboxamide Tosylate

92. 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide Tosylate

93. 4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-phenoxy} -pyridine-2-carboxylic Acid Methylamide-4-methylbenzenesulfonate

94. 4-{4-[3-(4-cl-3-trifluoromethyl-phenyl)-ureido]-phenoxy}-pyridine-2-carboxylic Acid Methylamide 4-methylbenzenesulfonate

95. 4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-n-(5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide Monomethanesulfonate

2.4 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₂₄ClF₃N₄O₆S
Molecular Weight	637.0 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	6
Exact Mass	636.1057179 g/mol
Monoisotopic Mass	636.1057179 g/mol
Topological Polar Surface Area	155 Å²
Heavy Atom Count	43
Formal Charge	0
Complexity	853
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Nexavar
PubMed Health	Sorafenib (By mouth)
Drug Classes	Antineoplastic Agent
Drug Label	NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate and its structural formula is...
Active Ingredient	Sorafenib tosylate
Dosage Form	Tablet
Route	Oral
Strength	eq 200mg base
Market Status	Prescription
Company	Bayer Hlthcare

2 of 2
Drug Name	Nexavar
PubMed Health	Sorafenib (By mouth)
Drug Classes	Antineoplastic Agent
Drug Label	NEXAVAR, a kinase inhibitor, is the tosylate salt of sorafenib. Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2-methylpyridine-2-carboxamide 4-methylbenzenesulfonate and its structural formula is...
Active Ingredient	Sorafenib tosylate
Dosage Form	Tablet
Route	Oral
Strength	eq 200mg base
Market Status	Prescription
Company	Bayer Hlthcare

4.2 Drug Indication

* Hepatocellular carcinoma:

Nexavar is indicated for the treatment of hepatocellular carcinoma.

* Renal cell carcinoma:

Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

* Differentiated thyroid carcinoma:

Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma, refractory to radioactive iodine.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

5.2 ATC Code

L01EX02

POST ENQUIRY